# US 2024/0390329 A1 · Application of channel blocker in preparation of drugs for treating and/or preventing liver fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390329 A1
- Document ID: US20240390329A1
- Status: Published application
- Kind: A1
- Application number: 18/462,388
- Filed: 2023-09-06
- Published: 2024-11-28
- Earliest claimed: 2023-05-22
- Assignees: Affiliated Hospital of Zunyi Medical University
- Applicants: Affiliated Hospital of Zunyi Medical University
- Inventors: Rui Xie; Jingyu Xu; Guowei Gong; Qian Du; Yanxia Hu; Jianhong Ding; Xianli Wu; Xiaoxu Yang; Jun Lou; Qi Liu; Zhuo Li
- Web page: https://patentgrep.com/patent/US20240390329A1

## CPC

- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An application of a channel blocker in preparation of drugs for treating and/or preventing liver fibrosis is provided, belonging to the field of biomedical technology. A new use of phenytoin sodium is provided. It is demonstrated that at the cell level, the phenytoin sodium can improve liver fibrosis by regulating autophagy and thus affecting the activation of hepatic stellate cells. In this situation, the efficacy of the phenytoin sodium on liver fibrosis is verified at the animal level by establishing a disease model, and the phenytoin sodium can be used to prepare drugs for treating and/or preventing liver fibrosis.

## Claims

### Claim 1

A application method of a channel blocker, comprising:
preparing a drug for at least one of treatment and prevention of liver fibrosis by using the channel blocker.

### Claim 2 (depends on 1)

The application method according to claim 1, wherein the channel blocker is a sodium channel blocker.

### Claim 3 (depends on 2)

The application method according to claim 2, wherein the sodium channel blocker is phenytoin (PHT) sodium.

### Claim 4 (depends on 1)

The application method according to claim 1, wherein the liver fibrosis comprises carbon tetrachloride (CCl4) induced liver fibrosis.

### Claim 5 (depends on 1)

The application method according to claim 1, wherein the drug comprises pharmaceutically acceptable excipients.

### Claim 6 (depends on 5)

The application method according to claim 5, wherein a dosage form of the drug is any medically recognized dosage form.

### Claim 7 (depends on 6)

The application method according to claim 6, wherein the dosage form of the drug comprises powder, an injection, a capsule, a tablet, and an oral liquid.

### Claim 8 (depends on 3)

The application method according to claim 3, comprising:
using the phenytoin sodium to prepare a drug to inhibit autophagy in liver tissue.

### Claim 9 (depends on 3)

The application method according to claim 3, comprising:
using the phenytoin sodium to prepare a drug to inhibit proliferation of hepatic stellate cells.

### Claim 10 (depends on 3)

The application method according to claim 3, comprising:
using the phenytoin sodium to prepare a drug to downregulate alpha-smooth muscle actin (α-SMA) in hepatocytes.
